Q32 Bio director granted 9,810 stock options

Q32 Bio Inc. director Arthur Tzianabos received a grant of stock options representing 9,810 shares of common stock.

Rhea-AI Filing Summary

Q32 Bio Inc. director Arthur Tzianabos received a grant of stock options representing 9,810 shares of common stock. The options have an exercise price of $12.64 per share and expire on June 11, 2036. Following this grant, he holds 9,810 options directly from this award in this filing.

According to the vesting terms, these options will vest and become exercisable in full on the earlier of June 12, 2027 or the date of Q32 Bio’s next annual meeting of stockholders, provided he continues to serve with the company through the applicable vesting date.

Insider Trade Summary

Grant/Award: 9,810 shares

Grant/Award 1 txn

Insider TZIANABOS ARTHUR

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	9,810	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 9,810 contracts (Direct)

Footnotes (1)

1. F1. The shares underlying this option shall vest and become exercisable in full upon the earlier of (i) June 12, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service on such vesting date.

Key Figures

Options granted: 9,810 options Exercise price: $12.64 per share Expiration date: June 11, 2036 +1 more

4 metrics

Options granted 9,810 options Stock Option (Right to Buy) grant

Exercise price $12.64 per share Stock option strike price

Expiration date June 11, 2036 Option term end

Underlying shares 9,810 shares Common stock underlying options

Key Terms

Stock Option (Right to Buy), exercise price, expiration date, vest and become exercisable

4 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

exercise price financial

"conversion_or_exercise_price: 12.6400"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"expiration_date: 2036-06-11T00:00:00.000Z"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

vest and become exercisable financial

"The shares underlying this option shall vest and become exercisable in full"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Q32 Bio (QTTB) director Arthur Tzianabos report in this Form 4?

Arthur Tzianabos reported receiving a grant of stock options for 9,810 shares of Q32 Bio common stock. These options were awarded as compensation and give him the right to buy shares at a fixed exercise price if vesting conditions are met.

How many Q32 Bio (QTTB) options were granted and at what exercise price?

The filing shows a grant of stock options covering 9,810 underlying Q32 Bio common shares with an exercise price of $12.64 per share. This price is the cost per share if he later chooses to exercise the options after they vest.

When do Arthur Tzianabos’s Q32 Bio (QTTB) stock options vest?

The options will vest and become exercisable in full on the earlier of June 12, 2027, or the date of Q32 Bio’s next annual stockholder meeting. Vesting requires his continued service with the company through that vesting date.

What is the expiration date of the Q32 Bio (QTTB) options granted to Arthur Tzianabos?

The granted stock options expire on June 11, 2036. After this expiration date, any unexercised options cease to be usable, so exercising can only occur between vesting and the stated expiration, subject to applicable company and plan rules.

Does the Form 4 show Arthur Tzianabos buying or selling Q32 Bio (QTTB) shares on the market?

The Form 4 reports a grant of derivative securities, specifically stock options, not an open-market purchase or sale. It records compensation-related acquisition of options, with no market buy or sell transactions disclosed in this particular filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/16/2026 - 04:30 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

TZIANABOS ARTHUR

(Last) (First) (Middle)

Q32 BIO INC.

830 WINTER STREET

(Street)

WALTHAM MASSACHUSETTS 02451

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Q32 Bio Inc. [ QTTB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/12/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$12.64	06/12/2026		A		9,810		(1)	06/11/2036	Common Stock	9,810	$0	9,810	D

Explanation of Responses:

1. The shares underlying this option shall vest and become exercisable in full upon the earlier of (i) June 12, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service on such vesting date.

	/s/ Eric Bell, Attorney-in-Fact	06/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)